BioCentury | Nov 27, 2020

With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision year. The positive allosteric modulator of GABA A receptor...
...includes SAGE-324, a positive allosteric modulator of GABA A receptor...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...clinical hold on the allosteric modulator of GABA A receptor...
BioCentury | Oct 17, 2020

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper had gained $8.80 to $27.80.Praxis expects readouts from three programs next year. Its allosteric modulator of GABA A receptor...
BioCentury | Oct 9, 2020

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months for...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

Wuhan-based XWPharma is developing novel formulations of existing neurology drugs designed to synchronize with the body’s natural rhythms, enabling it to avoid side effects associated with marketed agents....
BioCentury | Sep 15, 2020

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...synthetic analog of the endogenous neurosteroid allopregnanolone, which acts as a positive allosteric modulator of GABA A receptor.In...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Phase II testing for severe motor impairment following ischemic stroke. TARGET/MARKER/PATHWAY: Monoamine oxidase B (MAO-B); GABA A receptor... Claire Quang Korea Institute of Science and Technology Gwangju Institute of Science and Technology Monoamine oxidase B (MAO-B) GABA A receptor...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 1, 2020
Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

...on the neural expression patterns of the receptor subtypes. Danielle Kopke, Staff Writer Nan Fung Life Sciences Novartis AG GABA A receptor...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...induce a more rapid and sustained antidepressant effect without the sedative side effects of synaptic-only GABA A receptor...
Items per page:
1 - 10 of 635